Advertisement

Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer

  • Sarah L. Skoczen
  • Stephan T. SternEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1682)

Abstract

An important step in the early development of a nanomedicine formulation is the evaluation of stability and drug release in biological matrices. Additionally, the measurement of encapsulated and unencapsulated nanomedicine drug fractions is important for the determination of bioequivalence (pharmacokinetic equivalence) of generic nanomedicines. Unfortunately, current methods to measure drug release in plasma are limited, and all have fundamental disadvantages including non-equilibrium conditions and process-induced artifacts. The primary limitation of current ultrafiltration (and equilibrium dialysis) methods for separation of encapsulated and unencapsulated drug and determination of drug release is the difficulty in accurately differentiating protein bound and encapsulated drug. Since the protein binding of most drugs is high (>70%) and can change in a concentration- and time-dependent manner, it is very difficult to accurately account for the fraction of non-filterable drug that is encapsulated within the nanomedicine and how much is bound to protein. The method in this chapter is an improvement of existing ultrafiltration protocols for nanomedicine fractionation in plasma, in which a stable isotope tracer is spiked into a nanomedicine containing plasma sample in order to precisely measure the degree of plasma protein binding. Determination of protein binding then allows for accurate calculation of encapsulated and unencapsulated nanomedicine drug fractions, as well as free and protein-bound fractions.

Key words

Nanomedicine Drug release Stability Stable isotope Bioanalytical 

Notes

Acknowledgment

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References

  1. 1.
    Ambardekar VV, Stern ST (2015) NBCD pharmacokinetics and bioanalytical methods to measure drug release. In: Crommelin DJA, de Vlieger JSB (eds) Non-biological complex drugs: the science and the regulatory landscape. Springer International Publishing, Cham, Switzerland, pp 261–287. doi: 10.1007/978-3-319-16241-6_8 CrossRefGoogle Scholar
  2. 2.
    Liu X, Wright M, Hop CECA (2014) Rational use of plasma protein and tissue binding data in drug design. J Med Chem 57(20):8238–8248. doi: 10.1021/jm5007935 CrossRefPubMedGoogle Scholar
  3. 3.
    ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665–685. doi: 10.2165/00003088-200342070-00005 CrossRefPubMedGoogle Scholar
  4. 4.
    Skoczen S, McNeil SE, Stern ST (2015) Stable isotope method to measure drug release from nanomedicines. J Control Release 220(Pt A):169–174. doi: 10.1016/j.jconrel.2015.10.042 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  1. 1.Cancer Research Technology Program, Nanotechnology Characterization LaboratoryLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederickUSA

Personalised recommendations